Valuation
- Market cap
- 261,665,000
- Revenue TTM
- $13,000,000
- Net income TTM
- $-68,870,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -529.77%
- Debt to equity
- 0.00
Trading
- Volume
- 1,745,400
- Avg volume
- 647,298
- Day's range
- $6.74 – $7.28
- Shares out
- 36,292,000
- Stochastic %K
- 6%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $24.00
Company profile
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The compan...
Show more
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (925) 247-4481
- Website
- https://www.evommune.com
- Address
- 1891 Page Mill Road, Palo Alto, United States
Latest news
No headlines yet.
